<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05799638</url>
  </required_header>
  <id_info>
    <org_study_id>2023-01</org_study_id>
    <nct_id>NCT05799638</nct_id>
  </id_info>
  <brief_title>The Anti-myocardial Fibrosis Effect of Vericiguat in HFrEF</brief_title>
  <acronym>ANF-HF</acronym>
  <official_title>The Anti-myocardial Fibrosis Effect of Vericiguat in Patients With Heart Failure With Reduced Ejection Fraction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chongqing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chongqing Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vericiguat is a new medication therapy choice for the patients with heart failure with&#xD;
      reduced ejection fraction (HFrEF), in the latest trial, it met the expectation to reduce&#xD;
      incidence of death from cardiovascular causes or hospitalization for heart failure among&#xD;
      HFrEF patients. Myocardial fibrosis as a pathological change in heart failure, it contributes&#xD;
      to left ventricular dysfunction leading to development of the disease, experimental studies&#xD;
      have showed the potential prevention, or even reversal effect of sGC stimulators in left&#xD;
      ventricular hypertrophy and fibrosis. Our study is a prospective controlled clinical trial&#xD;
      aim to verify the anti-myocardial fibrosis effect of vericiguat in heart failure with reduced&#xD;
      ejection fraction.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this trial, the investigators will recruit 60 participants diagnosed with HFrEF (NYHA&#xD;
      class II-IV) and assign participants to two groups to receive standard medication therapy&#xD;
      with or without vericiguat (target 5mg qd) for 3 months. Before and after the 3-month&#xD;
      medication therapy, patients will receive cardiac magnetic resonance (CMR) assessment. The&#xD;
      primary endpoint is the change in extracellular volume (ECV) measured by CMR.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2023</start_date>
  <completion_date type="Anticipated">June 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Extracellular volume [ECV]</measure>
    <time_frame>Before and after 3 months of continuous treatment</time_frame>
    <description>Change in Extracellular volume [ECV]measured by cardiac magnetic resonance imaging [CMR]</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Left ventricular end-diastolic volume [LV-EDV] index</measure>
    <time_frame>Before and after 3 months of continuous treatment</time_frame>
    <description>Change in Left ventricular end-diastolic volume [LV-EDV] index measured by cardiac magnetic resonance imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart structure and function</measure>
    <time_frame>Before and after 3 months of continuous treatment</time_frame>
    <description>Change in left ventricular end-diastolic [LVD] dimension, left ventricular end-systolic [LVS] dimension, left atrial dimension [LAD] and pulmonary artery systolic pressure [PASP] measured by echocardiogram</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of circulating biomarkers of heart failure</measure>
    <time_frame>Before and after 3 months of continuous treatment</time_frame>
    <description>N-terminal pro-B-type natriuretic peptide [NT-proBNP]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New York Heart Association cardiac function classification</measure>
    <time_frame>Before and after 3 months of continuous treatment</time_frame>
    <description>NYHA cardiac function is graded from I to IV to estimate the cardiac function, the higher grade means the worse cardiac function and worse prognosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular end-systolic volume [LV-ESV] index</measure>
    <time_frame>Before and after 3 months of continuous treatment</time_frame>
    <description>Change in left ventricular end-systolic volume [LV-ESV] index measured by cardiac magnetic resonance imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>myocardial mass index</measure>
    <time_frame>Before and after 3 months of continuous treatment</time_frame>
    <description>Change in myocardial mass index measured by cardiac magnetic resonance imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>relative wall thickness</measure>
    <time_frame>Before and after 3 months of continuous treatment</time_frame>
    <description>Change in relative wall thickness measured by cardiac magnetic resonance imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>epicardial adipose tissue [EAT] thickness</measure>
    <time_frame>Before and after 3 months of continuous treatment</time_frame>
    <description>Change in epicardial adipose tissue [EAT] thickness measured by cardiac magnetic resonance imaging</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Heart Failure With Reduced Ejection Fraction</condition>
  <arm_group>
    <arm_group_label>Standard treatment with vericiguat group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HFrEF patients accept standard heart failure medication and Vericiguat therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard treatment group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>HFrEF patients accept standard medication therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vericiguat</intervention_name>
    <description>Standard HFrEF medication therapy according to the AHA and ESC guidelines and continuous vericiguat treatment for 12 weeks. Vericiguat will be started at 2.5 mg once daily and up-titrated to 5 mg at week 3, to 10 mg at week 5</description>
    <arm_group_label>Standard treatment with vericiguat group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 years who agreed to join in and signed the informed consent.&#xD;
&#xD;
          2. Diagnosed with HFrEF according to the 2022 AHA guidelines of 2022 AHA/ACC/HFSA&#xD;
             guideline and 2021 ESC guideline for the chronic heart failure.&#xD;
&#xD;
          3. Left ventricular ejection fraction ≤45% measured by CMR or echocardiogram.&#xD;
&#xD;
          4. NYHA classes II - IV&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who are receiving phosphodiesterase type 5 (PDE5) inhibitors or other sGC&#xD;
             stimulators therapy.&#xD;
&#xD;
          2. LVEF measured by the UCG &gt;45%.&#xD;
&#xD;
          3. Contraindication to CMR.&#xD;
&#xD;
          4. History of allergic or hypersensitivity to drugs involved in the trial or Congenital&#xD;
             glucose-galactose intolerance.&#xD;
&#xD;
          5. Patients with a known history of cancer, angioedema.&#xD;
&#xD;
          6. Patients with rheumatic valvular heart disease and significant congenital heart&#xD;
             disease.&#xD;
&#xD;
          7. Patients diagnosed with Hypertrophic obstructive cardiomyopathy, myocarditis, Fabry&#xD;
             disease, amyloidosis, sarcoidosis, or pericardial disease.&#xD;
&#xD;
          8. Acute coronary syndrome, including unstable angina, Non ST-elevation myocardial&#xD;
             infarction or ST-elevation myocardial infarction, or Coronary artery bypass grafting&#xD;
             (CABG) within 3 months prior to the trial start, or indication for Percutaneous&#xD;
             coronary intervention (PCI) or CABG at the trial start.&#xD;
&#xD;
          9. Interstitial lung disease , severe chronic obstructive pulmonary disease (COPD) and&#xD;
             chronic thrombotic pulmonary disease.&#xD;
&#xD;
         10. SBP≥180mmHg or DBP≥120mmHg at visit, DBP≤90mmHg or symptomatic hypotension.&#xD;
&#xD;
         11. Pregnant woman.&#xD;
&#xD;
         12. Chronic kidney disease and eGFR≤30ml/min/1.73m² or accepting long-term hemodialysis.&#xD;
&#xD;
         13. Hepatic insufficiency classified as Child-Pugh B or C.&#xD;
&#xD;
         14. Fatal or uncontrollable heart arrythmia e.g., symptomatic or persistence ventricular&#xD;
             tachycardia, ventricular rate&gt;150 bpm in AF patients.&#xD;
&#xD;
         15. Patients with pacemaker.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dongying Zhang, PhD</last_name>
    <phone>+8613608398395</phone>
    <email>zdy.chris@qq.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The first affiliated Hospital of Chongqing Medical University</name>
      <address>
        <city>Chongqing</city>
        <zip>400042</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Dongying Zhang, PhD</last_name>
      <phone>+8613608398395</phone>
      <email>zdy.chris@qq.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF, Butler J, Lam CSP, Ponikowski P, Voors AA, Jia G, McNulty SE, Patel MJ, Roessig L, Koglin J, O'Connor CM; VICTORIA Study Group. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2020 May 14;382(20):1883-1893. doi: 10.1056/NEJMoa1915928. Epub 2020 Mar 28.</citation>
    <PMID>32222134</PMID>
  </reference>
  <reference>
    <citation>Gonzalez A, Schelbert EB, Diez J, Butler J. Myocardial Interstitial Fibrosis in Heart Failure: Biological and Translational Perspectives. J Am Coll Cardiol. 2018 Apr 17;71(15):1696-1706. doi: 10.1016/j.jacc.2018.02.021.</citation>
    <PMID>29650126</PMID>
  </reference>
  <reference>
    <citation>Armstrong PW, Roessig L, Patel MJ, Anstrom KJ, Butler J, Voors AA, Lam CSP, Ponikowski P, Temple T, Pieske B, Ezekowitz J, Hernandez AF, Koglin J, O'Connor CM. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator: The VICTORIA Trial. JACC Heart Fail. 2018 Feb;6(2):96-104. doi: 10.1016/j.jchf.2017.08.013. Epub 2017 Oct 11.</citation>
    <PMID>29032136</PMID>
  </reference>
  <reference>
    <citation>Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022 May 3;145(18):e895-e1032. doi: 10.1161/CIR.0000000000001063. Epub 2022 Apr 1. Erratum In: Circulation. 2022 May 3;145(18):e1033. Circulation. 2022 Sep 27;146(13):e185. Circulation. 2023 Apr 4;147(14):e674.</citation>
    <PMID>35363499</PMID>
  </reference>
  <reference>
    <citation>McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, Burri H, Butler J, Celutkiene J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Kathrine Skibelund A; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021 Sep 21;42(36):3599-3726. doi: 10.1093/eurheartj/ehab368. No abstract available. Erratum In: Eur Heart J. 2021 Oct 14;:</citation>
    <PMID>34447992</PMID>
  </reference>
  <verification_date>April 2023</verification_date>
  <study_first_submitted>March 12, 2023</study_first_submitted>
  <study_first_submitted_qc>April 3, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2023</study_first_posted>
  <last_update_submitted>April 3, 2023</last_update_submitted>
  <last_update_submitted_qc>April 3, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chongqing Medical University</investigator_affiliation>
    <investigator_full_name>Dongying Zhang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>heart failure</keyword>
  <keyword>myocardial fibrosis</keyword>
  <keyword>vericiguat</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

